Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Current Liabilities (2016 - 2025)

Neurocrine Biosciences' Total Current Liabilities history spans 16 years, with the latest figure at $743.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 46.43% year-over-year to $743.4 million; the TTM value through Dec 2025 reached $743.4 million, up 46.43%, while the annual FY2025 figure was $743.4 million, 46.43% up from the prior year.
  • Total Current Liabilities reached $743.4 million in Q4 2025 per NBIX's latest filing, up from $638.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $743.4 million in Q4 2025 to a low of $190.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $462.0 million, with a median of $496.4 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: crashed 63.03% in 2021, then soared 118.76% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $245.8 million in 2021, then skyrocketed by 118.76% to $537.7 million in 2022, then grew by 21.78% to $654.8 million in 2023, then decreased by 22.46% to $507.7 million in 2024, then skyrocketed by 46.43% to $743.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Total Current Liabilities are $743.4 million (Q4 2025), $638.0 million (Q3 2025), and $546.3 million (Q2 2025).